18:26:27 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-06-25 Årsstämma 2025
2025-03-05 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-09-25 Kvartalsrapport 2024-Q2
2024-06-28 Kvartalsrapport 2024-Q1
2024-06-27 X-dag ordinarie utdelning SOFTX 0.00 NOK
2024-06-26 Årsstämma 2024
2024-03-27 Extra Bolagsstämma 2024
2024-03-20 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-09-26 Kvartalsrapport 2023-Q2
2023-06-21 Årsstämma 2023
2023-06-21 Kvartalsrapport 2023-Q1
2023-03-30 X-dag ordinarie utdelning SOFTX 0.00 NOK
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 X-dag ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 X-dag ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 X-dag ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Kvartalsrapport 2020-Q1
2020-06-30 Årsstämma 2020
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 X-dag ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50


ListaEuronext Growth Oslo
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo, Norge.
2022-06-28 07:59:58
The Board of SoftOx Solutions AS (the "Company"/"SoftOx") has entered into a
loan agreement with Almhaug Bolig AS, where the main shareholder is one of the
shareholders in SoftOx. Almhaug Bolig AS will provide the company with a
short-term loan of NOK 15 million.

The Company has experienced some delays both in connection with regulatory and
commercially processes and in the implementation of certain clinical studies. To
compensate for the liquidity burden caused by these delays, the company's main
shareholder has given the company a loan of NOK 15 million.

The Company is considering increasing the amount of the Loan to up to approx.
NOK 30 million to be raised from existing shareholders and certain professional
investors, subject to a minimum individual loan amount of NOK 1 million.

The net proceeds of the Loan will be used to fund the Company's ongoing project
and operating activities and for general corporate purposes.

Almhaug Bolig AS has committed to NOK 15 million of the Loan, of which NOK 5
million will be in form of refinancing of the convertible loan raised in October
2021 and the remaining NOK 10 million will be in cash. Almhaug Bolig AS is a
shareholder of the Company, in which the Company's ultimate main shareholder is
also a shareholder and chair of the board.

The Loan does not accrue any interests and the loan falls due 15 January 2024.
The individual lenders may convert the outstanding amount of the Loan into
shares in share capital increases with issuance of new shares in the Company and
set off of the lenders' claim for repayment of the Loan at any time prior to
maturity. The conversion price will be calculated based on a volume weighted
average trading price for the Company's shares prior to the Loan less 10%,
provided, however, that if the Company carries out a share offering at a price
lower than the conversion price, the lender will have the right to convert the
loan at the lower price in such offering shall apply.

Any new shares to be issued pursuant to the conversion right under the loan
agreement will be resolved by the Company's board of directors pursuant to the
authorization granted by the Company's annual general meeting on 12 May 2022 to
increase the Company's share capital (or any other authorization available to
the board of directors at such time).

The Board has considered alternative structures for raising funds. Following
careful considerations, the Board is of the view that it will be in the common
interest of the Company and its shareholders to raise funds through the
convertible loan setting aside the pre-emptive rights of the shareholders. By
structuring the funding as a convertible loan, the Company will be in a position
to raise capital before the summer, and in an efficient manner, with a lower
discount to the current trading price and with significantly lower risks
compared to a rights issue.

The Company expects that it will seek to raise additional funds during the next
12 months and will then seek to structure such offering in line with market
practice for capital raising, subject to prevailing market conditions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information
pursuant to article 7 of the Market Abuse Regulation, and is publicly disclosed
in accordance with article 17 of the Market Abuse Regulation and section 5-12 of
the Norwegian Securities Trading Act. The announcement is made by the contact

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech/biotech company based in Oslo with the aim of helping to combat major
threats to human health, namely the emergence of antimicrobial resistance (AMR),
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com